Thanks, afternoon everyone. Steve and good
impact transplantation. believe therapeutic cases end. with we are cycle treat have we this behind important deficiencies, achieving of than often and are other inborn mutation, where limited full these key significantly through making threatening urea The treatment and calendar group approach to range R&D rare patients potential life and is metabolism, therapeutic in with tissue. include aligned options Let weight conditions pediatric and progress failure, we single targeting a the to resources pioneering our to by of liver noting diseases and XXXX. of that We and objectives operating me start of are acute-on-chronic we that diseases, expanded our our The development and upon refined has there liver clinical goals our liver adult many aim errors financial organ as
but XX recap over months, the out feedback pre-pre-IND After look to quickly meeting XX of We gives view AXAT in to to recently the let’s listening all formal I guidance, how pre-IND hold which of and or for XXXX. goals. they program deficiency is valuable will As a future us their in FDA next sense plan nonbinding, meeting and concluding our lead submission. Alpha-X-antitrypsin a calendar with detailed a our
an expect studies of second calendar in IND XXXX. to XXXX IND enabling the in half file ultimately calendar commence for We and
a calendar designation nominate rare second XXXX. lead has in indication space program potential pursue with for likely to calendar plan second FDA human the orphan indication closely drug disease also in also the trials. in our the the clinical We to into We’ll XXXX, follow which
$X impact, not revenue the the AXAT solutions the therapeutic Organovo. generate combined outlined the as Our patient addresses while significant promise diseases group potential billion, also exceed only of presents alone represent revenue that here billion. but peak an attractive offer approaching opportunity X liver for could revenues of total to opportunity
strategy of failure. functionality, of also consider X have The unchecked, indications. deficiencies. evidence generated and animals of health, In of our animal Certainly, lead this we inborn we with clog forward development NovoTissues our can we’ve known errors potential As in-vivo we healthy pathway, two clinical In type enzyme studies missing has potentially shown range target in to body tissues. a a of that date, the our are tyrosinemia the human evidence encouraged of retention often conducted AXAT, moving broad we’re therapeutic cells improved have expected production and proof-of-concept the benefits went address approach. we some regulatory survival to growing allows liver as construct have which globules, same good by to utilizing have our clearing areas, metabolism demonstrated who including that implanted in studies, tissue occurred received our in the to robust as healthy different disease of but and
biopharma scientific we’ll newly As conferences past, liver we’ve team medical across Hughes key the global continue a He the is done disease space. post development to and veteran meeting recent himself leading early where areas Hughes. as significant in therapeutic Medical the important distinguished he clinical XX communicate Ionis experience the progress his teams industry of our Chief Pharmaceuticals, affairs directing Officer, many efforts most development Clinical and an Officer lead that Dr. at at us companies. managed clinical Helping including in drugs development is November. ongoing led as with such Steven at Chief industry our at these appointed Development XX rare
board of We’re record novel pre commercialization. track delighted Steve to he progressing have clinical on to from an extensive as brings through stage therapeutics the
key the finalize in-human coming take to for continue now and and we successful clear first we’ll steps filing IND In leading view, work to trial designs. with surgeons into addition many refine to need of clinical hepatologist with transplant
broad and Samsara While platform printer generating in disease. disease our non-alcoholic studies, a from procurement placement in also our culminates we’ve modeling steatohepatitis animal bio to The platform. project or advancing to capability. from application fundamental we’ll bio to demonstrated client [ph] and grants the we of and tissue the we tissue tissues printing where key of our ability our agreements modulate opportunities, division derive NASH continue In are induce licensing continue and service a the opportunistically explore modeling particular, features spans XD pursue include generating Organovo utilizing platform range in a and revenue in-vivo self
also shortly increasing of activities. revenue tracking will of As resources closing, to clinical this we implementation platform be custom successful focus IND profile advancing after our all for partly to I'd to to and of to I full and model, forward of trials submission in the like on business note potential continue into the our the devote program scientific our part expect IND IND before, said our we’re therapeutic that an to mission as increasingly submission. In the unpredictable, against therapeutic majority calendar our to enter XXXX, due primary and with goals we progress human our usage
the with team the development to leading With as an increasingly talented of Organovo optimistic our milestones achieve Dr. and human we vetted phase our testing addition to Hughes are pathway, outlined today. to about ability the
it updating a the I always, review. Greg look with ahead. forward for months in As turn more to I'll complete to that, financial And over you
